Maurie Markman, MD

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, and 2018 Giant of Cancer Care for Gynecological Cancers, discusses unmet needs in endometrial and cervical cancers.

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, and 2018 Giant of Cancer Care for Gynecological Cancers, discusses the treatment of ovarian cancer as a chronic disease.

The impact of subsequent lines of treatment on trial outcomes can be substantial, seriously challenging the relevance of OS as an objectively meaningful study endpoint.

Maurie Markman, MD, discusses how to address the important issue of survival following a cancer diagnosis.

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, 2018 Giant of Cancer Care for Gynecologic Cancers, discusses unmet needs in rare gynecologic cancers.

Since the introduction of platinum agents in ovarian cancer, it is reasonable to suggest there have been only limited changes in the basic paradigm of ovarian cancer management over the past several decades.

Maurie Markman, MD, discusses the steps that the scientific community needs to take to increase public acceptance of the vaccine against the human papillomavirus.

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, and 2018 Giant of Cancer Care for Gynecological Cancers, discusses the impact of precision medicine in ovarian cancer.

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, and 2018 Giant of Cancer Care® for Gynecological Cancers, discusses the concept of biosimilars in oncology.

Maurie Markman, MD discusses the importance of objective evidence when using a combination approach as opposed to a single-agent treatment.

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, and 2018 Giant of Cancer Care® for Gynecological Cancers, discusses the future of treatment for patients with ovarian cancer.

Maurie Markman, MD, discusses the search for less toxic strategies for the treatment of cancer that may lessen the negative impact on quality of life while maintaining therapeutic efficacy.

Maurie Markman, MD, discusses privacy concerns associated with genetic testing.

Maurie Markman, MD, discusses the clinical benefit of early-stage trials.

Maurie Markman, MD, reflects on how technological advances have impacted translational science and clinical medicine.

In recent years there has been much discussion about the serious limitations of the conduct and interpretation of randomized trials examining the utility of antineoplastic drug therapy.

Maurie Markman, MD, says that the acceleration in regulatory agency approvals for novel antineoplastic agents and the focus of biomarker discovery proves that this is the era of precision medicine.

Maurie Markman, MD, discusses the increasing criticism of the phase III randomized trial in oncology.

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, discusses the latest advances in treatment for gynecological malignancies and other tumor types.

Maurie Markman, MD, defines precision medicine in oncology.

The public’s faith in science, particularly in efforts related to health, is crucial for the successful implementation of strategies designed to improve the human condition, says Maurie Markman, MD.

Maurie Markman, MD, discusses the potential to employ germline data and knowledge about the presence of specific common, uncommon, or rare variants to cancer therapy.

Maurie Markman, MD, sheds light on the debate regarding the future direction of clinical investigation.

Maurie Markman, MD, shares his thoughts on the right-to-try bill, which would allow terminally ill patients to receive investigational drugs that have been studied in phase I trials without applying through the FDA’s expanded access program.

Maurie Markman, MD, discusses the cause and impact of the opioid addiction epidemic in the United States.

It is quite difficult for those not directly involved in the complex world of academic medicine to understand fully the process of individual professional advancement and the values that organizations place on the components required for achieving and maintaining tenure.

The impact of staggering increases in the cost of individual antineoplastic agents for patients and the overall healthcare system cannot be overstated, and there appears to be no realistic solution to the current dilemma that is acceptable to the parties involved in this ongoing debate.

One of the cardinal principles of modern medicine, as practiced in the United States, is active participation by patients—and often their families—in the process of clinical decision making.

Although median survival is a reasonable endpoint to highlight, it is only 1 of many relevant outcome factors to discuss, and, most important, this mathematical figure simply does not define the survival of any particular patient.

Decision support is only lightly touched upon in the academic oncology papers that are published almost daily suggesting a potential change in paradigms for management in a particular clinical setting.